- Home
- MTCH vs GKOS Comparison
MTCH vs GKOS Comparison
Compare MTCH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTCH
- GKOS
- Stock Information
- Founded
- MTCH 1986
- GKOS 1998
- Country
- MTCH United States
- GKOS United States
- Employees
- MTCH N/A
- GKOS N/A
- Industry
- MTCH Computer Software: Programming Data Processing
- GKOS Medical/Dental Instruments
- Sector
- MTCH Technology
- GKOS Health Care
- Exchange
- MTCH Nasdaq
- GKOS Nasdaq
- Market Cap
- MTCH 8.2B
- GKOS 8.4B
- IPO Year
- MTCH 2015
- GKOS 2015
- Fundamental
- Price
- MTCH $32.77
- GKOS $125.83
- Analyst Decision
- MTCH Buy
- GKOS Strong Buy
- Analyst Count
- MTCH 20
- GKOS 13
- Target Price
- MTCH $37.84
- GKOS $161.00
- AVG Volume (30 Days)
- MTCH 5.1M
- GKOS 722.6K
- Earning Date
- MTCH 02-04-2025
- GKOS 02-20-2025
- Dividend Yield
- MTCH 1.16%
- GKOS N/A
- EPS Growth
- MTCH N/A
- GKOS N/A
- EPS
- MTCH 2.02
- GKOS N/A
- Revenue
- MTCH $3,479,373,000.00
- GKOS $383,481,000.00
- Revenue This Year
- MTCH $1.05
- GKOS $22.69
- Revenue Next Year
- MTCH $5.23
- GKOS $26.76
- P/E Ratio
- MTCH $16.22
- GKOS N/A
- Revenue Growth
- MTCH 3.41
- GKOS 21.85
- 52 Week Low
- MTCH $27.66
- GKOS $83.90
- 52 Week High
- MTCH $38.84
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- MTCH 42.72
- GKOS 29.90
- Support Level
- MTCH $33.32
- GKOS $142.51
- Resistance Level
- MTCH $35.38
- GKOS $161.78
- Average True Range (ATR)
- MTCH 1.01
- GKOS 5.74
- MACD
- MTCH -0.20
- GKOS -1.65
- Stochastic Oscillator
- MTCH 1.06
- GKOS 2.39
About MTCH Match Group Inc.
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Hinge, BLK, Chispa, Match.com, OkCupid, PlentyOfFish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.